ArticleScientific reports2026
Silk fibroin-coated resveratrol solid lipid nanoparticles for diabetic wound healing.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Diabetic wounds remain a major clinical challenge due to delayed healing, persistent inflammation, and limited efficacy of existing therapies. Resveratrol possesses antioxidant, anti-inflammatory, and antibacterial properties but is restricted by poor solubility and rapid degradation. This study developed silk fibroin-coated resveratrol solid lipid nanoparticles (SF-RSLNs) to enhance resveratrol stability, provide controlled release, and improve therapeutic performance in diabetic wound healing. SF-RSLNs were fabricated using a microemulsion technique and optimized through a Box-Behnken design. The optimized nanoparticles exhibited a mean particle size of 222.1 nm, zeta potential of - 32 mV, entrapment efficiency of 85.7%, and drug loading of 10.2%. Characterization was performed using FTIR, SEM, and DLS analyses. In-vitro assessments included cytotoxicity (MTT), antioxidant activity (DPPH and ROS scavenging), antibacterial activity, scratch-wound healing, anti-inflammatory assays, and hemocompatibility evaluation. SF-RSLNs demonstrated sustained drug release (∼75% over 48 h), enhanced antioxidant activity (85% DPPH scavenging at 40 µg/mL), and significant wound closure (90% at 48 h). Antibacterial activity was improved, with inhibition zones of 18 mm against Staphylococcus aureus and 20 mm against Escherichia coli. SF-RSLNs also reduced TNF-α levels by 65% and increased IL-10 levels by 50%, while exhibiting excellent hemocompatibility. These findings indicate that SF-RSLNs serve as a multifunctional nanocarrier capable of enhancing resveratrol delivery and accelerating diabetic wound repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.